Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
Citryll has raised $89.7M in total funding. The most recent round was Series B. The last funding was announced in December 2024.
Citryll's investors include Seventure Partners, BioGeneration Ventures, Forbion Capital Partners, Novartis Venture Fund, Johnson & Johnson Innovation JJDC.
Citryll is headquartered in Oss, The Netherlands.
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
Citryll is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Citryll — Funding & Investors." VCBacked, December 9, 2024, https://www.vcbacked.co/company/citryll. Accessed October 30, 2026.
VCBacked. (2024). Citryll — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/citryll
{{cite web |title=Citryll — Funding & Investors |url=https://www.vcbacked.co/company/citryll |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated